We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.
Location: Germany
Employees: 11-50
Total raised: $26.14M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 17.03.2024 | High-Tech ... | htgf.de |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.05.2026 | Series A | $12M | Bayern Kap... |
| 24.03.2023 | Series A | $14.14M | - |
Mentions in press and media 7
| Date | Title | Description |
| 04.05.2026 | mbiomics Raises $12M in Series A Funding | mbiomics GmbH, a Neuried, Germany-based techbio company developing microbiome-based therapeutics for severe and chronic diseases, raised $12M in Series A funding. Backers included MIG Fonds and Bayern Kapital. The company intends to use the... |
| 29.04.2026 | MIG Fonds and Bayern Kapital Back mbiomics €30M Raise | In a significant milestone for the European ‘techbio’ industry, Mbiomics GmbH, based in Munich, announced that it had finalised the third and final closing of its Series A investment round, which now totals €30 million following a €12 milli... |
| 24.03.2023 | Microbiome therapeutics biotech mbiomics raises EUR 13 million in first closing of Series A round | March 23, 2023 |
| 24.03.2023 | Biotech Financing Roundup: Mbiomics, Flare Therapeutics, EpiBiologics & More | Spring is a time of growth and renewal, and a new slate of biotech companies has raised cash to grow their drug pipelines filled with potential new treatments for cancer, neurological disorders, and more. Here’s a look back at some recent b... |
| 23.03.2023 | mbiomics Raises €13M in Series A Funding | mbiomics, a Munich, Germany-based microbiome biotech company developing microbiome-based therapeutics, raised €13M in Series A funding. The round was led by MIG, with participation from High-Tech Gründerfonds, Bayern Kapital and private see... |
| 23.03.2023 | Microbiome therapeutics developer mbiomics receives €13 million A-round financing with lead investor MIG Capital | MIG Capital invests in Munich-based microbiome therapeutics developer mbiomics GmbH in an A-round financing. The biotech company uses its customized, high-precision bacterial profiling platform to accelerate the development of effective mic... |
| - | mbiomics | “mbiomics” |